IGF-1 LR3 – LIVE ALPHA LABS
US$ 20.30
dihexa clinical trials humans human studies Dihexa Clinical trial diversity
Description
(2024) Breast Cancer Res, 26: 179
BPC-157 doesn't interfere with GLP-1 receptor binding, doesn't alter insulin signaling, and doesn't affect the appetite-suppression pathways that GLP-1 medications target
ANDREW HUBERMAN: Well, Im certainly going to get back to jumping rope now that weve resurrected it in this conversation
This study found that IN orexin-A administration essentially restores olfactory performance
